Dasatinib for a child with Philadelphia chromosome–positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy

Imatinib has improved outcomes in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (all). Minimal residual disease (mrd) is a useful tool for predicting leukemia relapse. However, there is no consensus on how to treat children with elevation of BCR-ABL transcripts bu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Curr Oncol
Päätekijät: Wu, K.H., Wu, H.P., Weng, T., Peng, C.T., Chao, Y.H.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Multimed Inc. 2015
Aiheet:
Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4530816/
https://ncbi.nlm.nih.gov/pubmed/26300669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2719
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia